{"id": "236967", "url": "https://fevir.net/resources/Evidence/236967", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/comparator-only-evidence"], "versionId": "69", "lastUpdated": "2025-10-07T17:12:54.639Z"}, "name": "End_stage_kidney_disease_Comparator_Evidence_from_MAGICapp_313960", "note": [{"text": "Defined as a GFR below 45 or a GFR below 70 AND macroalbuminuria (ACR > 200 mg/g); derived from RECODe (https://sanjaybasu.shinyapps.io/recode/)."}], "title": "MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes", "author": [{"name": "Computable Publishing\u00ae: MAGIC-to-FEvIR Converter"}], "citeAs": "MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing\u00ae: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236967. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/236967. Computable resource at: https://fevir.net/resources/Evidence/236967#json.", "status": "active", "contact": [{"telecom": [{"value": "support@computablepublishing.com", "system": "email"}]}], "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/", "publisher": "Computable Publishing LLC", "relatesTo": [{"type": "part-of", "targetReference": {"type": "Composition", "display": "MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "MAGIC-5288-j1Wqrn-conversion-report", "assigner": {"display": "Computable Publishing LLC"}}}}], "statistic": [{"quantity": {"value": 0.119}, "description": "Risk 11.9%", "statisticType": {"coding": [{"code": "STATO:0000607", "system": "https://fevir.net/sevco", "display": "proportion"}]}}], "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"code": "ACSN", "system": "http://terminology.hl7.org/CodeSystem/v2-0203", "display": "Accession ID"}]}, "value": "236967", "system": "https://fevir.net/FOI", "assigner": {"display": "Computable Publishing LLC"}}, {"type": {"text": "outcomeId"}, "value": "313960", "system": "https://app.magicapp.org/#/guidelines"}, {"type": {"text": "picoId"}, "value": "85798", "system": "https://app.magicapp.org/#/guidelines"}, {"type": {"text": "sectionId"}, "value": "73215", "system": "https://app.magicapp.org/#/guidelines"}], "useContext": [{"code": {"code": "evidence-communication", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"code": "ComparatorOnlyEvidence", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "ComparatorOnlyEvidence"}]}}], "studyDesign": [{"text": "NO_STUDY"}], "resourceType": "Evidence", "synthesisType": [{"text": "NOTSET"}], "variableDefinition": [{"observed": {"type": "Group", "display": "GLP-1 RA Group in Adults with type 2 diabetes", "reference": "Group/236948", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-comparator-group-MAGIC-5288-j1Wqrn-comparator-85394-C-85798", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "description": "Adults with type 2 diabetes -- GLP-1 RA", "variableRole": "population"}, {"observed": {"type": "EvidenceVariable", "display": "End-stage kidney disease", "reference": "EvidenceVariable/236965", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-313960", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "description": "End-stage kidney disease", "variableRole": "outcome"}], "description": "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide."}